A micronutrient-fortified young child formula improves the iron and vitamin D status of healthy young European children: a randomized, double-blind controlled trial
Results
The study sample consisted of 318 predominantly Caucasian (~95%) children. The difference in SF and 25(OH)D change between the treatment groups were +6.6µg/l (95% confidence interval (CI) 1.4 to 11.7 , p=0.013) and +16.4nmol/l (95% CI 9.5 to 21.4, p<0.001), respectively. The probability of ID and VDD after the intervention was lower in the YCF group compared to the CM group (OR of 0.42, 95% CI 0.18 to 0.95, p=0.036 and OR of 0.22, 95% CI 0.01 to 0.51, p<0.001, respectively).
Conclusion
Micronutrient-fortified YCF use for 20 weeks preserves iron status and improves vitamin D status in healthy young children in Western-Europe.
A micronutrient-fortified young child formula improves the iron and vitamin D status of healthy young European children: a randomized, double-blind controlled trial
I N T R O D U C T I O N
Deficiency of micronutrients is a global health problem, also in industrialised countries, contributing to the global burden of disease. Iron deficiency (ID) and vitamin D deficiency (VDD) are two of the most common micronutrient deficiencies in young children worldwide.
1 ID can lead to iron deficiency anemia (IDA) 2 and both these conditions are associated with impaired neurodevelopment [3] [4] [5] [6] . Vitamin D is suggested to have an important role in immune system functioning and in preventing cancers, whereas VDD can lead to rickets. 7, 8 Despite national nutritional recommendations, the iron and vitamin D intake of young children in Europe has been shown to be often insufficient to prevent ID and VDD. [9] [10] [11] [12] [13] Furthermore, although the use of vitamin D supplements is associated with a lower prevalence of VDD, compliance seems to be low. 7, 9, 10 To increase compliance, the fortification of commonly used food products has been suggested. This produces a more gradual increase in serum micronutrient concentration and, if consumed on a regular and frequent basis, fortified products will maintain body stores of nutrients more efficiently and more effectively than will intermittent supplements. 1 Several international trials have shown beneficial effects of food fortification (i.e. milk, bread and margarine) on iron [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] and on vitamin D [24] [25] [26] [27] status in children. Milk is a popular vehicle for delivering fortification due to its wide availability and acceptance. However, randomized controlled trials investigating the effect of this strategy in young European children are scarce. Existing studies differ in dosage of the fortification and in outcome parameters, which hampers comparison of study results. 14, 15, 17, 23, 25 Moreover, the influence of an infection (e.g. on serum ferritin (SF)) or the season (on vitamin D status) on outcome parameters is not always taken into account.
The primary objective of this study was to investigate the effect of a micronutrient-fortified young child formula (YCF) given for 20 weeks on ferritin concentrations of healthy 12-36 months old children living in Western-Europe, in comparison with the use of non-fortified cow's milk (CM). Secondary objectives were to establish the effect of the intervention on the prevalence of ID and IDA, serum 25-hydroxyvitamin D (25(OH)D) concentrations, and the prevalence of VDD.
Inclusion and exclusion criteria
Children aged 12 to 36 months with a stable health status (i.e. without any known chronic or recent acute disease) were eligible for this study. The children were familiar with and currently drinking milk products, and were expected to have a study product intake of at least 150 ml per day. Exclusion criteria were being born preterm (<32 weeks or <37 weeks with a birth weight <1800 gram), known infection during the last week or infection needing medical assistance or treatment during the last two weeks, known hemoglobinopathies, any case of anemia treated in the last three months, a blood transfusion received within the last six months, the presence of a relevant congenital abnormality, chromosomal disorder or severe disease (such as major congenital heart disease or Down's syndrome), having a disorder requiring a special diet (such as food intolerance or food allergy or complaints such as reflux, constipation and cramps), the current use of anti-regurgitation, anti-reflux or laxative medication, participation in any other study involving investigational or marketed products within two weeks prior to entering the study, known allergy or intolerance to components of the study products (e.g. milk powder, lactose or fish protein), and vaccination with a live or live-attenuated vaccine received during the last two weeks. Finally, parents had to be able to understand the local language and read and fill out questionnaires.
Study procedure
Subjects were recruited in two ways, based on the local situation at the individual sites. In the Netherlands and the UK, parents of eligible subjects were informed about the study during a pre-operative visit before an elective, non-emergency surgical procedure (e.g. urological surgeries, inguinal or umbilical hernia A micronutrient-fortified young child formula improves the iron and vitamin D status of healthy young European children: a randomized, double-blind controlled trial operations or ear-nose-throat procedures). After written informed consent was obtained, the first blood draw was combined with the placement of an intravenous catheter needed for administering general anesthesia. The subjects from Germany were recruited during a regular visit to their pediatrician. After taking the blood sample, the included children were randomly allocated to receive either micronutrient-fortified YCF (Test product) or non-fortified CM (Control product) for a period of 20 weeks. A computer model was used for block randomization in which stratification was applied for country and sex. Parents (and their children), investigators and treating physicians were blinded to product allocation by coding of the cans containing the study products. Subsequently, parents answered questions about their child's demographic and socio-economic characteristics, day care centre attendance, sun exposure and medical history. The food intake was measured by a food frequency questionnaire, which was adapted and translated from previously published dietary questionnaires. [28] [29] [30] Micronutrient intake was calculated using the Dutch nutrient databank called 'Nederlands Voedingsstoffenbestand' (NEVO). 31 The results reflected the intake in the period of one month before the baseline visit.
During the intervention period, parents were asked not to change their child's dietary habits, including the use of supplements. After 1, 5 and 15 weeks, parents were contacted by phone to discuss study product compliance and completion of diaries. These diaries included daily study product intake, possible adverse events (AE) and serious adverse events (SAE), and the use of medication. Diaries on stool frequency and consistency were completed 7 days before the last 2 scheduled visits (at week 10 and 20) . Stool frequency was measured as the number of stools passed on each day of the 7 days and stool consistency was measured on an ordered 5-point scale with pictures (1-watery; 2-soft, pudding like; 3-soft formed; 4-dry formed; 5-dry hard pellets). Halfway through the study, parents were asked to visit the study center in order to collect new study product and to discuss potential issues. After 20 weeks, in all three countries, a second venous blood sample was taken while subjects visited the hospital or clinic for a last time (Figure 1 ). During all three visits (baseline, 10 weeks and 20 weeks), height (length) and weight were measured. Body weight was measured to the nearest 0.1 kilogram using a calibrated weighing scale. Height was measured to the nearest 0.2 centimeter, standing and without wearing shoes, using a calibrated stadiometer. In those children who were not able to stand, length was measured lying down with the use of a length board, to 0.2 centimeter precision. Weight-for-age Z-scores, height/length-for-age Z-scores and Body mass index (BMI) (weight divided by height/length²)-for-age Z-scores following World Health Organization (WHO) growth charts were calculated.
Figure 1 Flow chart of the study design
This figure shows the study procedure during the 20-weeks intervention period and the 2-weeks follow-up period.
Abbreviations: C, phone contact; V, visit.
Test and Control product: YCF and CM
The detailed nutrient profiles of both study products are shown in Table 1 . The Test product was a commercially available micronutrient-fortified YCF containing 1.2 mg/100 ml iron and 1.7 µg/100 ml vitamin D. The Control product was a nonfortified CM that contained 0.02 mg/100 ml iron and no vitamin D. The energy levels of both products were comparable (i.e. 46 kcal/100 ml for CM compared to 50 kcal/100 ml for YCF). Both YCF and CM were supplied in powdered form with instructions for preparing the milk by diluting the powder with water. The study products were produced, provided and coded (for blinding purposes) by Nutricia Cuijk B.V., Cuijk, the Netherlands (commissioned by Danone Nutricia Research, Utrecht, the Netherlands). A micronutrient-fortified young child formula improves the iron and vitamin D status of healthy young European children: a randomized, double-blind controlled trial SF and serum 25(OH)D were analyzed by using an Abbott Architect i2000 immunology analyzer with a chemiluminescent immunoassay and a chemiluminescent micro-particle immunoassay, respectively.
ID was defined as SF <12 µg/l, according to criteria of the WHO. 2 IDA was defined as ID in combination with a hemoglobin (Hb) concentration <110 g/l, also according to the WHO.
2 Ferritin is an acute phase protein that may increase when an infection is present, even in the presence of low iron stores. Therefore, high sensitivity C-reactive protein (hsCRP), also an acute phase protein, was determined in all venous blood samples, and all children with elevated hsCRP concentrations (≥10 mg/l) were excluded from the analyses regarding ID and IDA.
VDD was defined as serum 25(OH)D <50 nmol/l as this is the cut-off level recommended by most experts. 7, 10, 32 As previously described 9 , mean annual vitamin D concentrations were calculated from the single values to adjust for seasonal variation in circulating 25(OH)D concentrations, by using the cosinor model of Sachs et al 33 .
Statistical analysis
Sample size calculations were based on the primary parameter (SF) applying data from a study of Szymlek-Gay et al. 20 Assuming a difference between treatment groups in SF change (from baseline to endpoint) of 8.1 µg/l (± 21 µg/l), a total of 216 subjects (108 per group) were required for a statistical power of 0.8, using an alpha of 0.05 in a two-sided t-test. In addition, in order to account for stratification and dropout (estimated at 25%), a total of 288 subjects were anticipated to be required for inclusion in the study.
Statistical analyses, described in a statistical analysis plan which was finalized before unblinding of the study, were performed using Statistical Package for the Social Sciences (SPSS) (version 21.0; SPSS Inc., Chicago, IL, USA). As a first step, the distribution of variables was assessed using histograms/Q-Q-plots. Subsequently, categorical variables were summarized by frequency and percentage distributions, and normally distributed continuous variables were summarized by means and standard deviations (SD). Non-normally distributed continuous variables were expressed as medians and 25 th and 75 th percentiles (Q1 and Q3). The basic principle of our analyses was to analyze data on an intention-to-treat (ITT) basis, in which all children of whom there is information, are analyzed in the groups to which they were originally allocated, irrespective of whether they actually followed the treatment regime. Vitamin D status and Hb concentrations A micronutrient-fortified young child formula improves the iron and vitamin D status of healthy young European children: a randomized, double-blind controlled trial were analyzed in this ITT study sample. Subsequently, analyses regarding iron status (including IDA) were performed in the modified ITT study sample. This sample included all subjects from the ITT study sample in whom normal hsCRP concentrations (<10 mg/l) were measured at both baseline and at the end of the study.
The effect of the study products on SF and serum 25(OH)D concentration was investigated using linear regression analyses, while its effect on the prevalence of both micronutrient deficiencies was determined by performing logistic regression analyses. In principle, these analyses were performed while adjusting for sex and country (stratification factors), age, micronutrient status at baseline and iron or vitamin D intake (from food and supplements) at baseline. In case of vitamin D analyses, we also performed adjustment for sun exposure ('at least 1 hour outside per day').
Finally, all above mentioned analyses, including adjustments for the predefined variables, were also performed in the two 'Per Protocol' (PP) samples. These samples consisted of subjects from the ITT and the modified ITT sample that demonstrated "good compliance" with instructions for consuming the assigned study product. "Good compliance" was defined as consuming at least 151 ml of study product per day on at least 80% of the days during the last 28 days of study product intake. All confidence intervals (CI) are presented two-sided with a confidence level of 95%. Statistical significance was defined as p<0.05.
R E S U LT S Study sample and baseline characteristics
Because of a higher rate of dropouts than anticipated, 318 subjects were finally included in the ITT study sample: 158 in the YCF group and 160 in the CM group (Figure 2 ). This ITT sample consisted of 264 children from Germany (83.0%), 42 children from the Netherlands (13.2%) and 12 children from the UK (3.8%). Table  2 and Table 3 show the baseline characteristics and the baseline iron and vitamin D status of the two treatment groups, respectively. These tables show a higher educational level and working status of the parents of the YCF group than of the CM group, although more data on this are missing in the CM group than in the YCF group. Furthermore, the CM group had a higher iron intake from milk and a higher vitamin D intake from food than the YCF group (Table 2 ). Figure 2 shows the numbers of children included in our different study groups and analysis sets. There were no differences in the number of or reasons for early termination (Figure 2 ) or in the percentage of children demonstrating "good compliance" (69.6% vs. 71.9%, p=0.659) between YCF and CM users. The aforementioned observed differences in education level, working status and iron and vitamin D intake between CM and YCF users were also found in our modified ITT sample and the PP/modified PP sample (data not shown).
A micronutrient-fortified young child formula improves the iron and vitamin D status of healthy young European children: a randomized, double-blind controlled trial A
This figure illustrates the flow of our study sample. Children with elevated hsCRP concentrations (≥ 10 mg/l) were excluded from the analyses regarding iron status to prevent falsely elevated or normal ferritin concentrations in case of an infection. Subsequently, the PP groups consist of children that demonstrated "good compliance" with instructions for consuming the assigned study product. "Good compliance" was defined as consuming at least 151 ml of study product per day on at least 80% of the days during the last 28 days of study product intake. Abbreviations: CM, cow's milk; hsCRP, high sensitivity C-reactive protein; ITT, intention-to-treat; PP, per protocol; YCF, young child formula.
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Iron status and ID/IDA prevalence
In the (complete) modified ITT sample, the difference in change from baseline in SF between the treatment groups was +6.6 µg/l (95% CI 1.4 to 11.7, p=0.013). The estimated mean (± standard error of the mean (SEM)) change in SF concentration from baseline was -4.9 ± 2.2 µg/l for the CM group and +1.7 ± 2.4 µg/l for the YCF group (Table 3) . Subsequently, we performed explorative analyses in which the modified ITT sample was divided into four subgroups representing categories of 'most frequently consumed daily volume during the last four weeks' (1-150ml/day, 151-300ml/day, 301-500ml/day and >500ml/day). The effect sizes in these subgroups were analyzed while adjusting for sex, country and baseline SF concentration. In children consuming >500ml/day, the group difference in change from baseline in SF was +11.2 µg/l (95% CI 1.8 to 20.6). Change from baseline (mean ± SD) + 3.5 ± 9.1 + 3.1 ± 8.9
Vitamin D A micronutrient-fortified young child formula improves the iron and vitamin D status of healthy young European children: a randomized, double-blind controlled trial Table 4 shows the prevalence rates of ID and IDA before and after the intervention. The probability of ID after the intervention was lower in the YCF group compared to the CM group (odds ratio (OR) of 0.42, 95% CI 0.18 to 0.95, p=0.036). The IDA prevalence rates were too low to evaluate the effect of the intervention on IDA prevalence.
Hb concentrations and anemia
At baseline, 18.9% (60/318) of the children were anemic; 23 children in the YCF group and 37 children in the CM group. After the intervention, 4 YCF users and 13 CM users were anemic (p=0.021). In contrast, the mean change from baseline in Hb was comparable for YCF and CM users (Table 3) . Iron deficiency anemia (n (%)) - A micronutrient-fortified young child formula improves the iron and vitamin D status of healthy young European children: a randomized, double-blind controlled trial
Vitamin D status and VDD prevalence
In the (complete) ITT sample, the difference in change from baseline in 25(OH)D between the treatment groups was +16.4 nmol/l (95% CI 9.5 to 21.4, p<0.001).
The estimated mean (± SEM) change in 25(OH)D concentration from baseline was -7.2 ± 2.5 nmol/l for the CM group and +9.2 ± 2.8 nmol/l for the YCF group (Table  3) . Subsequently, we performed explorative analyses in which we determined the effect sizes in subgroups based on 'most frequently consumed daily volume during the last four weeks' while adjusting for sex, country and baseline 25(OD)D concentration. In children consuming >500ml/day, the group difference in change from baseline in 25(OH)D was +18.1 nmol/l (95% CI 3.0 to 33.2). Table 4 shows the prevalence rates of VDD before and after the intervention. The probability of VDD after the intervention was lower in the YCF group compared to the CM group (OR of 0.22, 95% CI 0.01 to 0.51, p<0.001).
Iron and vitamin D deficiency
At baseline, 8.2% (12/147) of the YCF group and 5.6% (8/143) of the CM group were iron as well as vitamin D deficient. These prevalence rates increased in the CM group to 15.3% (15/98) and decreased for YCF users to 4.0% (4/101), after 20 weeks of study product intake.
Per protocol analyses PP and modified PP analyses confirmed the results from the ITT/modified ITT analyses, although the effect sizes were larger in the PP analyses (data not shown).
Safety of study products: adverse events, gastrointestinal tolerance and growth
Overall, there were no statistically significant differences in the number and severity of reported AEs between the YCF and CM group (data not shown).
Of the reported AEs (in total, 939 in 258 subjects), 33 events in 27 subjects were considered to be related to the study product. The majority of these supposedly related AEs compromised gastrointestinal complaints. In total, there were 30 reports of diarrhea in 26 subjects (17%) from the YCF group versus 17 reports of diarrhea in 14 subjects (9.2%) from the CM group (p=0.061). In both groups, most of these reports were documented in the first week after the start of the study product and the diarrhea lasted for less than five days (data not shown). The complaints were not severe and most of the complaints resolved without any medication. Furthermore, there were 9 SAEs reported in 8 subjects. These events were diverse and evenly distributed over the treatment groups (data not shown).
All were considered not to be related to the study product. Table 5 shows the stool characteristics (frequency and consistency) recorded before each hospital/clinic visit, by treatment group. No statistically significant differences in gastrointestinal tolerance were observed between the treatment groups.
Finally, there were also no statistically significant differences in the anthropometric data (i.e. weight-for-age Z-score, height/length-for-age Z-score and BMI-for-age Z-score) between the two treatment groups during the intervention period (data not shown). This table shows the stool frequency and consistency of the included children during the intervention period. There were no statistically significant differences between the two treatment groups. These analyses were performed in all children from the intention-to-treat sample that actually drank any study product. A micronutrient-fortified young child formula improves the iron and vitamin D status of healthy young European children: a randomized, double-blind controlled trial
D I S C U S S I O N
This is the first randomized double-blind controlled trial to describe the effect of micronutrient-fortified YCF on both the iron and vitamin D status of healthy 12-36 months old children in Western-Europe. The results of this study indicate that daily consumption of YCF for a period of 20 weeks preserves iron status and improves vitamin D status in young European children. Furthermore, neither study product was related to the incidence of serious adverse events. The use of YCF may therefore be an effective and practical strategy to prevent ID and VDD in young European children.
Iron status
We observed a modest increase in SF in the children consuming YCF. Explorative analyses based on type of milk before start of the study (formula or cow's milk) showed a higher increase in SF in original cow's milk users than in original formula users (data not shown). Therefore, young children consuming cow's milk will probably benefit the most from micronutrient-fortified YCF. Normally, you expect a decrease of SF over time since blood volume expands rapidly during growth requiring increasing erythropoiesis with use of stored iron and subsequent decrease of SF concentrations. 14, 15, 20, 23 Since the SF concentration increased modestly in the YCF group, we suggest that the use of micronutrient-fortified YCF preserves iron stores in young European children.
Four European studies also report on the effect of fortified formula on iron status 14, 15, 17, 23 , although only two of them 14, 17 used formula with a comparable iron content of 1.2 mg/100 ml. First, Daly et al. investigated the hematological effects of a follow-on formula in a group of inner city toddlers whose mothers had already switched to pasteurised cow's milk by 6 months of age. SF concentrations in formula users remained stable, while these decreased significantly in the toddlers that continued on cow's milk. 14 The second study that used the same iron dosage, focused on the mental and psychomotor developmental indices at the age of 18 months after 9 months use of fortified formula. The authors report significantly higher SF concentrations at 18 months in the fortified formula users compared to non-fortified formula and cow's milk users. Unfortunately, they do not report on SF concentrations at baseline. 17 Therefore, the results of our study are only comparable to the study from Daly et al. However, they included younger children, had a longer intervention period, and did not specify details on the ethnicity and socioeconomic status of the participating children. Furthermore, they did not take into account the influence of a possible infection on SF concentrations. These differences in study design make it difficult to compare results.
Vitamin D status
Our observed increase in serum 25(OH)D concentrations in the YCF group is confirmed by a study from Hower et al. among German children. 25 In contrast, Madsen et al. found a decrease in serum 25(OH)D concentration in both formula and cow's milk users in Denmark. 26 In this latter study, a lower fortification dosage of only 0.38 µg vitamin D/100 ml was used as compared to 1.7 µg/100 ml in our YCF. This lower fortification dosage may not be sufficient to maintain adequate serum 25(OH)D concentrations.
The VDD prevalence in our study decreased in the YCF group, while it increased in the CM group (to 33.3%). In the previously mentioned study of Hower et al., higher prevalence rates up to 79.2% were found in cow's milk users. 25 In this study, the influence of vitamin D fortified formula (2.85 µg vitamin D/100 ml) on vitamin D status was investigated in older children (2-6 years). Vitamin D status was determined before (October/November) and after winter (late February). It is known that the risk for VDD increases during the winter 7, 10 , which may explain that their VDD prevalence rates are higher than in our study.
Only a minority of the children (~30%) in our study received vitamin D supplements (mean content 10.7 µg/day), although policies regarding vitamin D supplementation exist in all three participating countries. This emphasizes the need for new strategies, like the use of fortified food products.
Advantage of fortification with iron and vitamin D (and other micronutrients)
Most of the previously mentioned RCTs studied the effect of single iron-or single vitamin D-fortified food products. However, a comprehensive review by Best el al. showed that multi-micronutrient fortification, like our YCF, results in more positive effects on biochemical indicators of micronutrient status. 34 In general, it is believed that micronutrients can interact with each other (for example, by competing for the same transporter) and hereby lead to a different absorption of other micronutrients. 34, 35 For example, ID and VDD seem to influence each other in a negative way, but the precise pathogenesis is unclear. [36] [37] [38] [39] Vitamin D is suggested to increase the storage and retention of iron by reducing the activity of pro-inflammatory cytokines that inhibit iron absorption. On the other hand, it is known that ID impairs the intestinal absorption of fat and the fat-soluble vitamin A and therefore maybe also the absorption of fat-soluble vitamin D. Moreover, iron is a cofactor for the A micronutrient-fortified young child formula improves the iron and vitamin D status of healthy young European children: a randomized, double-blind controlled trial enzyme 1α-hydroxylase which is responsible for the hydroxylation of 25(OH)D to 1,25(OH) 2 D (40) . Combined fortification of iron and vitamin D may therefore have a synergistic effect on iron and vitamin D status. On the other hand, the bioavailability of iron also depends on the composition of the diet. Food products containing heme iron (e.g. meat) are better absorbed than those containing non-heme iron (e.g. vegetables, milk). Furthermore, several factors enhance (e.g. vitamin C) or inhibit (e.g. calcium) iron absorption. The amount of calcium is lower and the amount of vitamin C is higher in our YCF than in our CM and this could have also influenced the found effect of our YCF on change in iron status. Another impact of multi-micronutrient fortification is that, besides iron, several other micronutrients can also influence Hb concentrations.
34
Safety of micronutrient-fortified YCF Iron could theoretically increase pro-oxidant stress with potential adverse effects, including infection risk, while it may affect stool pattern as well. However, consistent with previous reports 41 , we neither observed a difference in the frequency and severity of adverse events 15 nor in the stool characteristics between YCF and CM users. Consistent with two other studies, we also did not find differences in anthropometric parameters between YCF and CM users.
14,17

Strengths and limitations
The strength of our study is that it was a randomized double-blind controlled trial in a well-defined sample of healthy young Caucasian children in Western-Europe. Furthermore, we took into account the influence of infections and the season on iron and vitamin D status parameters, respectively.
The majority of our study sample consisted of German children and almost all children were from the Caucasian race. This may hamper generalization of our results to other parts of the world with non-Caucasian children. However, we believe that country and race may influence baseline status, but not modify the effect of our intervention. Another limitation of our study is the use of an adapted food frequency questionnaire that was not validated for determining iron and vitamin D intake in young children. However, these kind of questionnaires have been found suitable for determining iron and vitamin D intake in infants and preschoolers. 42 Finally, the percentages of dropout (mostly due to non-acceptance of the study product), although similar for both treatment groups, were higher than expected. Around 40% of the children consumed cow's milk prior to the start of the study. During the intervention period, these children were exposed to milk with a different consistency and possibly a different taste. This can explain A micronutrient-fortified young child formula improves the iron and vitamin D status of healthy young European children: a randomized, double-blind controlled trial the refusal of some children to drink the study products. Future studies should therefore investigate the best form and taste of fortified YCF.
CO N C LU S I O N
Daily use of micronutrient-fortified YCF, instead of non-fortified CM, during 20 weeks preserves iron status and improves vitamin D status in 12-36 months old children in Western-Europe. The current recommendations state that cow's milk is acceptable after the age of 1 year, although the iron and vitamin D intake in these children, including the use of vitamin D supplements, is insufficient to prevent ID and VDD. YCF, as part of a toddler's diet, could play a role in ensuring sufficient intake of certain micronutrients. The long-term benefits of fortified YCF on neurodevelopment and overall health remain to be elucidated in future studies.
